Transplant Diagnostics Market

The transplant diagnostics market is expected to reach USD 8.14 billion by 2031 from USD 5.61 billion in 2026, at a CAGR of 7.8%. The demand for accurate and rapid transplant diagnostic procedures is increasing due to the rising number of organ transplantation procedures and the growing prevalence of chronic diseases that necessitate transplantation. Improving donor-recipient compatibility assessments and enhancing transplantation outcomes are becoming increasingly important. Additionally, the focus on research and development in molecular diagnostics is driving the adoption of advanced technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These technologies provide faster, more accurate, and more efficient transplant diagnostic testing. Furthermore, growing public and private investments, along with increased government support for strengthening transplantation and diagnostic infrastructure, are expected to accelerate the development and adoption of advanced transplant diagnostic technologies in the coming years.

In October 2024, QIAGEN N.V. (Netherlands) expanded its automated liquid biopsy portfolio to enhance applications in oncology, prenatal care, and organ transplantation. This expansion aimed to improve automated workflows for non-invasive liquid biopsy applications and to increase the efficiency of sample preparation and molecular diagnostic procedures used in organ transplantation.

To know about the assumptions considered for the study download the pdf brochure

In March 2026, F. Hoffmann-La Roche Ltd. (Switzerland) launched the cobas MPX-E assay, a new 4-in-1 donor screening test that detects HIV, HCV, HBV, and HEV in a single test. The assay is intended to improve laboratory efficiency, reduce turnaround time, and support high-throughput blood donor screening through Roche’s fully automated cobas x800 systems.

The key players operating in this market are Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), bioMérieux (France), Becton, Dickinson and Company (US), Illumina, Inc. (US), DiaSorin S.p.A. (Italy), CAREDX, INC. (US), and Werfen (Spain). Market players have implemented various strategies to enhance their market position, including advanced product development, partnerships, expansions, and acquisitions. These organic and inorganic strategies have enabled market participants to expand their reach across different geographies by offering advanced transplant diagnostic tests.

Thermo Fisher Scientific Inc. (US) is a key player in the transplant diagnostics market. The company's robust presence in molecular diagnostics, extensive product portfolio, and comprehensive global distribution network have enabled it to maintain a strong position in the industry. Thermo Fisher Scientific is committed to enhancing its transplant diagnostics capabilities through ongoing product development and technological advancements in molecular testing. The company's expertise in PCR and sequencing technologies supports a range of applications, including histocompatibility testing, infectious disease testing, donor-recipient compatibility testing, and genomic profiling. Additionally, Thermo Fisher's diverse customer base, which includes hospitals, transplant centers, research institutes, and diagnostic laboratories, further reinforces its position in the transplant diagnostics market.

F. Hoffmann-La Roche Ltd. (Switzerland) is a key player in the transplant diagnostics market. The company boasts a diversified portfolio of molecular diagnostics, a robust global presence, and a strong focus on innovation, which collectively enable it to maintain a competitive edge in the industry. Roche is committed to developing advanced molecular diagnostic solutions that enhance testing efficiency, accuracy, and laboratory workflow capabilities. The company's strong research and development capabilities, along with its well-established distribution network, further bolster its global market presence. Additionally, Roche's emphasis on automated, high-throughput molecular diagnostic technologies addresses the growing demand for advanced transplant diagnostic procedures. For example, in March 2026, Roche launched the cobas MPX-E assay, a 4-in-1 donor screening test that detects HIV, HCV, HBV, and HEV in a single test. This assay is designed to improve laboratory efficiency, reduce turnaround time, and facilitate high-throughput donor screening workflows.

Market Ranking

Thermo Fisher Scientific Inc. (US) has emerged as a leading player in the transplant diagnostics market, thanks to its robust molecular diagnostics portfolio, advanced PCR and sequencing technologies, and a comprehensive global presence. F. Hoffmann-La Roche Ltd. (Switzerland) is also a significant participant, leveraging its diverse molecular diagnostics portfolio, automated diagnostic systems, and strong commitment to innovation and product development.

Bio-Rad Laboratories, Inc. (US) has secured a prominent position in the transplant diagnostics market by offering a wide range of molecular testing solutions and demonstrating expertise in clinical diagnostics and research applications. QIAGEN N.V. (Netherlands) plays an important role in the market due to its strong capabilities in sample preparation technologies and molecular assay solutions, as well as its increased focus on transplant diagnostic applications. Additionally, bioMérieux (France) maintains its standing in the transplant diagnostics market through its molecular diagnostic technologies, infectious disease testing capabilities, and ongoing investments in research and development.

Related Reports:

Transplant Diagnostics Market by Product & Service (Instrument, Software), Technology (PCR, NGS), Application [Diagnostic (Infectious Disease, HLA) Research], Type [Solid Organ (Heart), Bone Marrow], End User (Hospital) & Region -Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]